Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
beta-lactamase inhibitor
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
complicated urinary tract infections |
| gptkbp:ATCCode |
J01DI54
|
| gptkbp:CASNumber |
1205113-88-3
|
| gptkbp:combines |
gptkb:meropenem
|
| gptkbp:developedBy |
gptkb:Rempex_Pharmaceuticals
|
| gptkbp:hasMolecularFormula |
C12H16BNO5S
|
| https://www.w3.org/2000/01/rdf-schema#label |
vaborbactam
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Vabomere
|
| gptkbp:mechanismOfAction |
inhibits serine beta-lactamases
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
gptkb:Klebsiella_pneumoniae_carbapenemase_(KPC)
|
| gptkbp:bfsParent |
gptkb:Carbavance
gptkb:Vabomere |
| gptkbp:bfsLayer |
6
|